Follow
Brian Hamman
Brian Hamman
HotSpot Therapeutics, Arvinas Inc., Lexicon Pharmaceuticals, Vertex Pharma.
Verified email at hotspotthera.com
Title
Cited by
Cited by
Year
Lessons in PROTAC design from selective degradation with a promiscuous warhead
DP Bondeson, BE Smith, GM Burslem, AD Buhimschi, J Hines, ...
Cell chemical biology 25 (1), 78-87. e5, 2018
7002018
BiP maintains the permeability barrier of the ER membrane by sealing the lumenal end of the translocon pore before and early in translocation
BD Hamman, LM Hendershot, AE Johnson
Cell 92 (6), 747-758, 1998
5661998
The advantages of targeted protein degradation over inhibition: an RTK case study
GM Burslem, BE Smith, AC Lai, S Jaime-Figueroa, DC McQuaid, ...
Cell chemical biology 25 (1), 67-77. e3, 2018
5452018
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
BE Smith, SL Wang, S Jaime-Figueroa, A Harbin, J Wang, BD Hamman, ...
Nature communications 10 (1), 131, 2019
4062019
The aqueous pore through the translocon has a diameter of 40–60 ┼ during cotranslational protein translocation at the ER membrane
BD Hamman, JC Chen, EE Johnson, AE Johnson
Cell 89 (4), 535-544, 1997
3871997
Identification of a membrane-spanning domain of the thiol-activated pore-forming toxin Clostridium perfringens perfringolysin O: an α-helical to β-sheet transition identifiedá…
LA Shepard, AP Heuck, BD Hamman, J Rossjohn, MW Parker, KR Ryan, ...
Biochemistry 37 (41), 14563-14574, 1998
3711998
Identification and characterization of Von Hippel-Lindau-recruiting proteolysis targeting chimeras (PROTACs) of TANK-binding kinase 1
AP Crew, K Raina, H Dong, Y Qian, J Wang, D Vigil, YV Serebrenik, ...
Journal of medicinal chemistry 61 (2), 583-598, 2018
2582018
A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases
SM Rodems, BD Hamman, C Lin, J Zhao, S Shah, D Heidary, L Makings, ...
Assay and drug development technologies 1 (1), 9-19, 2002
2082002
Miniaturized FRET assays and microfluidics: key components for ultra-high-throughput screening
L Mere, T Bennett, P Coassin, P England, B Hamman, T Rink, ...
Drug Discovery Today 4 (8), 363-369, 1999
1641999
Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain
W Kostich, BD Hamman, YW Li, S Naidu, K Dandapani, J Feng, A Easton, ...
Journal of Pharmacology and Experimental Therapeutics 358 (3), 371-386, 2016
942016
Optical probes and assays
BA Pollok, BD Hamman, SM Rodems, LR Makings
US Patent 6,410,255, 2002
942002
Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma
BA Harrison, NA Whitlock, MV Voronkov, ZY Almstead, K Gu, R Mabon, ...
Journal of medicinal chemistry 52 (21), 6515-6518, 2009
902009
Location and domain structure of Escherichia coli ribosomal protein L7/L12: site specific cysteine cross-linking and attachment of fluorescent probes
RR Traut, D Dey, DE Bochkariov, AV Oleinikov, GG Jokhadze, B Hamman, ...
Biochemistry and cell biology 73 (11-12), 949-958, 1995
761995
Tetramethylrhodamine Dimer Formation as a Spectroscopic Probe of the Conformation of Escherichia coli Ribosomal Protein L7/L12 Dimers (∗)
BD Hamman, AV Oleinikov, GG Jokhadze, DE Bochkariov, RR Traut, ...
Journal of Biological Chemistry 271 (13), 7568-7573, 1996
721996
Protein-protein interaction inducing technology
J Wang, AP Crew, H Dong, T Neklesa, B Hamman
US Patent App. 15/477,966, 2017
632017
Discovery of a type III inhibitor of LIM kinase 2 that binds in a DFG-out conformation
NC Goodwin, G Cianchetta, HA Burgoon, J Healy, R Mabon, ED Strobel, ...
ACS medicinal chemistry letters 6 (1), 53-57, 2015
612015
Dimer/monomer equilibrium and domain separations of Escherichia coli ribosomal protein L7/L12
BD Hamman, AV Oleinikov, GG Jokhadze, RR Traut, DM Jameson
Biochemistry 35 (51), 16680-16686, 1996
611996
Profound obesity secondary to hyperphagia in mice lacking kinase suppressor of ras 2
JP Revelli, D Smith, J Allen, S Jeter‐Jones, MK Shadoan, U Desai, ...
Obesity 19 (5), 1010-1018, 2011
592011
Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma
BA Harrison, ZY Almstead, H Burgoon, M Gardyan, NC Goodwin, J Healy, ...
ACS medicinal chemistry letters 6 (1), 84-88, 2015
542015
Rotational and conformational dynamics of Escherichia coli ribosomal protein L7/L12
BD Hamman, AV Oleinikov, GG Jokhadze, RR Traut, DM Jameson
Biochemistry 35 (51), 16672-16679, 1996
501996
The system can't perform the operation now. Try again later.
Articles 1–20